Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study of MK-2206, an AKT Inhibitor, in Pediatric Patients With Recurrent or Refractory Solid Tumors or Leukemia

NCT01231919 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT01231919
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01231919 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study of MK-2206, an AKT Inhibitor, in Pediatric Patients With Recurrent or Refractory Solid Tumors or Leukemia
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 1
Overall status
Completed
Start date
January 31, 2011
Completion date
Not reported
Enrollment
45 (actual)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

accelerated phase chronic myelogenous leukemia, acute leukemias of ambiguous lineage, acute myeloid leukemia/transient myeloproliferative disorder, acute undifferentiated leukemia, aggressive nk-cell leukemia, atypical chronic myeloid leukemia, bcr-abl1 negative, blastic phase chronic myelogenous leukemia, blastic plasmacytoid dendritic cell neoplasm, childhood burkitt lymphoma, childhood chronic myelogenous leukemia, childhood diffuse large cell lymphoma, childhood grade iii lymphomatoid granulomatosis, childhood immunoblastic large cell lymphoma, childhood nasal type extranodal nk/t-cell lymphoma, chronic eosinophilic leukemia, chronic myelomonocytic leukemia, chronic neutrophilic leukemia, chronic phase chronic myelogenous leukemia, intraocular lymphoma, juvenile myelomonocytic leukemia, mast cell leukemia, myeloid/nk-cell acute leukemia, noncutaneous extranodal lymphoma, post-transplant lymphoproliferative disorder, primary central nervous system hodgkin lymphoma, primary central nervous system non-hodgkin lymphoma, progressive hairy cell leukemia, initial treatment, prolymphocytic leukemia, recurrent childhood acute lymphoblastic leukemia, recurrent childhood acute myeloid leukemia, recurrent childhood anaplastic large cell lymphoma, recurrent childhood grade iii lymphomatoid granulomatosis, recurrent childhood large cell lymphoma, recurrent childhood lymphoblastic lymphoma, recurrent childhood small noncleaved cell lymphoma, recurrent grade 1 follicular lymphoma, recurrent grade 2 follicular lymphoma, recurrent grade 3 follicular lymphoma, recurrent mantle cell lymphoma, recurrent marginal zone lymphoma, recurrent mycosis fungoides/sezary syndrome, recurrent small lymphocytic lymphoma, recurrent/refractory childhood hodgkin lymphoma, refractory chronic lymphocytic leukemia, refractory hairy cell leukemia, relapsing chronic myelogenous leukemia, secondary acute myeloid leukemia, small intestine lymphoma, splenic marginal zone lymphoma, unspecified childhood solid tumor, protocol specific, waldenström macroglobulinemia